The Hepatoprotective Effects of Phak Khom in Hepatitis Treatment
DOI:
Abstract
This study investigated the hepatoprotective effects of Phak Khom (Andrographis paniculata) using in vitro and in vivo models. Phak Khom extract showed dose-dependent cytotoxicity on hepatocyte cells, significantly reducing cell viability at concentrations above 100 µg/mL. In addition, the extract showed a reduction in oxidative stress markers, with a 40% reduction in reactive oxygen species (ROS) and inhibition of pro-inflammatory cytokines (TNF-α and IL-6). In vivo, Phak Khom treatment in rats resulted in a significant reduction in liver enzyme levels (ALT and AST), indicating improved liver function. Histopathological analysis revealed decreased liver necrosis and fibrosis, while oxidative stress markers such as malondialdehyde (MDA) were decreased, and superoxide dismutase (SOD) activity was increased. Statistical analysis confirmed the efficacy of the extract at both low and high doses. These findings validate the traditional use of Phak Khom in liver-related disorders and support its potential as an adjunct therapy for hepatitis. However, further clinical studies, especially randomized controlled trials, are essential to confirm its safety and efficacy in humans, and to explore its synergy with conventional treatments.
Downloads
Views : 190
Downloads : 91
References
World Health Organization, “Hepatitis B,” WHO, 2021. [Online]. Available: https: //www.who.int/news-room/fact-sheets/detail/hepatitis-b.
A. Asase, “Ghana’s herbal medicine industry: prospects, challenges and ways forward from a developing country perspective,” Frontiers in Pharmacology, vol. 14, 2023.
A. S. K. Ali, H. A. Makeen, G. Khuwaja, H. A. Alhazmi, M. Sharma, A. Koty, M. I. Mazahirul, H. Parveen, A. Mohammed, S. Mukhtar, and M. F. Alam, “Assessment of the phytochemical profile, antioxidant capacity, and hepatoprotective effect of Andrographis paniculata against CCl₄-induced liver dysfunction in Wistar albino rats,” Medicina (Kaunas), vol. 59, no. 7, 2023.
C. Smirne, E. Croce, D. Di Benedetto, V. Cantaluppi, C. Comi, P. P. Sainaghi, R. Minisini, E. Grossini, and M. Pirisi, “Oxidative stress in non-alcoholic fatty liver disease,” Livers, vol. 2, no. 1, pp. 30–76, 2022.
S. Britza, R. Byard, and I. Musgrave, “Traditional Chinese medicine-associated nephrotoxicity and the importance of herbal interactions – An overview,” Pharmacological Research - Modern Chinese Medicine, vol. 3, no. 1, Apr. 2022,
A. Kaewdech, S. Nawalerspanya, S. Assawasuwannakit, N. Chamroonkul, S. Jandee, and P. Sripongpun, “The use of Andrographis paniculata and its effects on liver biochemistry of patients with gastrointestinal problems in Thailand during the COVID-19 pandemic: A cross-sectional study,” Scientific Reports, vol. 12, no. 1, 2022.
N. Bhatt, J. Johnson, S. Chaskar, and D. Chitre, “Randomized clinical trial of an Ayurvedic formulation, BV-7310 in alcoholic liver disease,” Indian Journal of Clinical Practice, vol. 33, no. 9, 2023.
S. K. Law, D. C. T. Au, A. W. N. Leung, and C. Xu, “A mini-review of traditional Chinese medicines on liver diseases,” Pharmacological Research - Modern Chinese Medicine, vol. 7, 2023.
M. Foghis, S. G. Bungau, A. F. Bungau, C. M. Vesa, A. L. Purza, A. G. Tarce, D. M. Tit, A. Pallag, T. Behl, S. S. ul Hassan, and A.-F. Radu, “Plants-based medicine implication in the evolution of chronic liver diseases,” Biomedicine & Pharmacotherapy, vol. 158, 2023.
H. Liang, Q. Huang, L. Zou, P. Wei, J. Lu, and Y. Zhang, “Methyl gallate: Review of pharmacological activity,” Pharmacological Research, vol. 194, 2023.
Q. Lv, J. Long, and L. Yang, “Current state of knowledge on the antioxidant effects and mechanisms of action of polyphenolic compounds,” All Articles, Aug. 31, 2021.
B. Pandey, R. Baral, A. Kaundinnyayana, et al., “Promising hepatoprotective agents from the natural sources: A study of scientific evidence,” Egypt Liver Journal, vol. 13, 2023.
Q. Cai, W. Zhang, Y. Sun, L. Xu, M. Wang, X. Wang, S. Wang, and Z. Ni, “Study on the mechanism of andrographolide activation," Frontiers in Neuroscience, vol. 16, Sep. 2022
T. Kisseleva and D. Brenner, “Molecular and cellular mechanisms of liver fibrosis and its regression,” Nat. Rev. Gastroenterol. Hepatol., vol. 18, pp. 151–166, 2021.
S. Rodimova, A. Mozherov, V. Elagin, M. Karabut, I. Shchechkin, D. Kozlov, D. Krylov, A. Gavrina, N. Bobrov, V. Zagainov, E. Zagaynova, and D. Kuznetsova, “Effect of hepatic pathology on liver regeneration: The main metabolic mechanisms causing impaired hepatic regeneration,” Int. J. Mol. Sci., vol. 24, no. 11, p. 9112, 2023,
A. A. J. Jabbar, Z. Z. Alamri, M. A. Abdulla, N. A. Salehen, Z. S. A. Al Sinawi, and S. M. Alfaifi, “Hepatoprotective effects of Gynura procumbens against thioacetamide-induced cirrhosis in rats: Targeting inflammatory and oxidative stress signalling pathways,” Heliyon, vol. 9, no. 9, 2023.
Y.-S. Lee and E. Seki, “In vivo and in vitro models to study liver fibrosis: Mechanisms and limitations,” Cellular and Molecular Gastroenterology and Hepatology, vol. 16, no. 3, pp. 355–367, 2023.
